The EU took note of the WHO recommendations not to use Gilead remedsivir for the treatment of hospitalized COVID-19 patients, but has not yet changed its authorization for use. The European regulatory authority has requested complete data from the WHO-led study and will evaluate them together with other available data to determine if changes are necessary.
The EU took note of the WHO recommendations not to use Gilead remedsivir for the treatment of hospitalized COVID-19 patients, but has not yet changed its authorization for use. The European regulatory authority has requested complete data from the WHO-led study and will evaluate them together with other available data to determine if changes are necessary. 
reuters.com
English (US) 